Liquid Biopsy Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026 Liquid biopsy market is anticipated to value over US$ 8.4 billion by the end of 2026 and expanding at a CAGR of over 20% during the forecast period, 2019 to 2026. Cancer is one of the most prevalent diseases owing to which the need for various cancer treatments. Techniques like biopsy are used to understand the tumour nature so that cancer can be managed correctly which can be eliminated eventually. There are two techniques used, one is the conventional method of solid tissue biopsy and other is the newly introduced liquid biopsy technique. Metastatic relapse evaluation and minimal invasiveness are some of the advantages of using liquid biopsy over solid tissue biopsy which would increase its demand resulting in the growth of the market. A further boost to the market growth will be contributed by factors like patient preference to get minimally invasive therapy, increase in the number of cancer cases and increase in the disposable income among patients suffering from cancer. Also, using liquid biopsy tests to identify and treat rare cancers will provide multiple opportunities for key market players to establish and expand their business. Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=203&page=requestsample Insights on Global Liquid Biopsy Market: By Region • North America • Europe • Asia Pacific • Latin America • Rest of the World North America is the major shareholder of the global market as it has a high adoption rate of liquid biopsy test and thus is expected to show a higher market growth rate during the forecast period. Europe follows North America and it is primarily dominated by the UK, France and Germany. The market spaces with the most number of opportunities for manufacturers are the Asia Pacific and Latin America as these markets are yet to explored and penetrated properly. These regions will, therefore, experience a higher market growth rate during the forecast period. Rest of the World possesses a small share of the global market due to limited adoption. By Circulating Biomarker • Circulating tumour DNA • Circulating Tumour Cells (CTC) • Extracellular Vesicles • Others Circulating tumour DNA is one of the most analysed biomarkers due to its capability of detecting cancer in earlier stages and prediction of cancer recurrence. CT-DNA and a combination of various biomarker analysis have provided sensitivity ranging from 69% to 98% for five different types of cancer according to a study by Cohen et al. These are the reasons that this market segment will receive good traction during the forecast period. Exosomes, which are small vesicles, were thought to be as waste disposal units initially. But recent researches suggest that they play an important role in the initiation of cancer and also in its progression and metastasis. Due to this new revelation, this market segment will get a significant amount of traction during the forecast period and especially in the developed economy market regions like North America and Europe as they adopt newer technologies with ease. Purchase a Copy of this Premium Research Report & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=203&page=askfordiscount By End User • Hospitals • Cancer Research Centres • Diagnostic Laboratories Hospitals dominate this market segment due to the provision of advanced infrastructure and introduction of multi-speciality hospitals. It is expected that they will dominate the global market in the forecast period as well. Competitive Landscape: • Biocept Inc. • Qiagen Corp. • Roche Diagnostics • RainDance Technologies Biocept’s Target Selector liquid biopsy follows all the clinical regulations listed by the National Comprehensive Cancer Network (NCCN) and thus focusses on clinically-actionable cancer biomarkers that will lead to an efficient tumour identification and treatment which will provide them higher traction in the market during the forecast period. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Global Liquid Biopsy Market by Biomarker Type, by End-User, and by Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America, and Rest of the World • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions • Profiling of companies to evaluate their market shares, strategies, financials and core competencies Table of Contents 1.1. Introduction 1.1.1.1. Scope and Objective 1.1.1.2. Assumptions and Acronyms 1.1.1.3. Forecast Factors 1.1.1.4. Research Methodology 1.2. Executive Summary 1.2.1.1. Industry Cluster Analysis 1.2.1.2. Competition Matrix 1.2.1.3. Strategies Recommendations 1.3. Market Definition 1.3.1.1. Report Scope (Inclusions & Exclusions) 1.3.1.2. Market Segmentation 1.4. Global Liquid Biopsy Market Overview 1.4.1.1. Global Liquid Biopsy Market Revenue (USD Mn) 1.5. Key Inclusions 1.5.1.1. Porter’s Five Force analysis 1.5.1.2. Market Dynamics 1.5.1.3. Industry Trends 1.5.1.4. Regulatory Guidelines 1.5.1.5. Opportunities in Liquid Biopsy 1.6. Competition Dynamics 1.6.1.1. Company Share Analysis (2018) 1.6.1.2. Top 10 Product Pricing by Region 1.7. Global Liquid Biopsy Market Revenue (USD Mn), 2018-2026 by Biomarker Type 1.7.1.1. Key Market Findings 1.7.1.2. Long Term ROI Segments 1.7.1.3. Revenue Opportunity Influencing Factors 1.7.1.4. Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 20182026 1.7.1.4.1.1. ctDNA 1.7.1.4.1.2. Exosomes 1.7.1.4.1.3. CTC cells 1.8. Global Liquid Biopsy Market Revenue (USD Mn), 2018-2026 by End User 1.8.1.1. Key Market Findings 1.8.1.2. Long Term ROI Segments 1.8.1.3. Revenue Opportunity Influencing Factors 1.8.1.4. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.8.1.4.1.1. Hospitals 1.8.1.4.1.2. Cancer Research Centres 1.8.1.4.1.3. Diagnostic Laboratories 1.9. Global Liquid Biopsy Market Revenue (USD Mn), 2018-2026 by Region 1.9.1.1. Key Market Findings 1.9.1.2. Long Term ROI Segments 1.9.1.3. Revenue Opportunity Influencing Factors 1.9.1.4. Market Revenue (USD Mn) Assessment and Forecast by Region,2026 1.9.1.4.1.1. North America 1.9.1.4.1.2. Latin America 1.9.1.4.1.3. Europe 1.9.1.4.1.4. Asia Pacific 1.9.1.4.1.5. Rest of world 1.10. North America Liquid Biopsy Market Revenue (US$ Mn), 2018-2026 1.10.1.1. Key Market Findings 1.10.1.2. Long Term ROI Segments 1.10.1.3. Revenue Opportunity Influencing Factors 1.10.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.10.1.4.1.1. US 1.10.1.4.1.2. Canada 1.10.1.5. Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 20182026 1.10.1.5.1.1. ctDNA 1.10.1.5.1.2. Exosomes 1.10.1.5.1.3. CTC cells 1.10.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.10.1.6.1.1. Hospitals 1.10.1.6.1.2. Cancer Research Centres 1.10.1.6.1.3. Diagnostic Laboratories 1.11. Latin America Liquid Biopsy Market Revenue (US$ Mn), 2018-2026 1.11.1.1. Key Market Findings 1.11.1.2. Long Term ROI Segments 1.11.1.3. Revenue Opportunity Influencing Factors 1.11.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.11.1.4.1.1. Brazil 1.11.1.4.1.2. Mexico 1.11.1.4.1.3. Argentina 1.11.1.4.1.4. Rest of Latin America 1.11.1.5. Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 20182026 1.11.1.5.1.1. ctDNA 1.11.1.5.1.2. Exosomes 1.11.1.5.1.3. CTC cells 1.11.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.11.1.6.1.1. Hospitals 1.11.1.6.1.2. Cancer Research Centres 1.11.1.6.1.3. Diagnostic Laboratories 1.12. Europe America Liquid Biopsy Market Revenue (US$ Mn), 2018-2026 1.12.1.1. Key Market Findings 1.12.1.2. Long Term ROI Segments 1.12.1.3. Revenue Opportunity Influencing Factors 1.12.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.12.1.4.1.1. Germany 1.12.1.4.1.2. France 1.12.1.4.1.3. Spain 1.12.1.4.1.4. UK 1.12.1.4.1.5. Russia 1.12.1.4.1.6. Poland 1.12.1.4.1.7. Rest of Europe 1.12.1.5. Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 20182026 1.12.1.5.1.1. ctDNA 1.12.1.5.1.2. Exosomes 1.12.1.5.1.3. CTC cells 1.12.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.12.1.6.1.1. Hospitals 1.12.1.6.1.2. Cancer Research Centres 1.12.1.6.1.3. Diagnostic Laboratories 1.13. Asia Pacific America Liquid Biopsy Market Revenue (US$ Mn), 2018-2026 1.13.1.1. Key Market Findings 1.13.1.2. Long Term ROI Segments 1.13.1.3. Revenue Opportunity Influencing Factors 1.13.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.13.1.4.1.1. Emerging Asia 1.13.1.4.1.1.1.1. China 1.13.1.4.1.1.1.2. India 1.13.1.4.1.1.1.3. ASEAN-5 1.13.1.4.1.1.1.4. Rest of Emerging Asia 1.13.1.4.1.2. Japan 1.13.1.5. Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 20182026 1.13.1.5.1.1. ctDNA 1.13.1.5.1.2. Exosomes 1.13.1.5.1.3. CTC cells 1.13.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.13.1.6.1.1. Hospitals 1.13.1.6.1.2. Cancer Research Centres 1.13.1.6.1.3. Diagnostic Laboratories 1.14. Rest of World America Liquid Biopsy Market Revenue (US$ Mn), 2018-2026 1.14.1.1. Key Market Findings 1.14.1.2. Long Term ROI Segments 1.14.1.3. Revenue Opportunity Influencing Factors 1.14.1.4. Market Revenue (USD Mn) Assessment and Forecast by Country, 2018-2026 1.14.1.4.1.1. Middle East 1.14.1.4.1.2. South Africa 1.14.1.4.1.3. North Africa 1.14.1.4.1.4. Rest of World 1.14.1.5. Market Revenue (USD Mn) Assessment and Forecast by Biomarker Type, 20182026 1.14.1.5.1.1. ctDNA 1.14.1.5.1.2. Exosomes 1.14.1.5.1.3. CTC cells 1.14.1.6. Market Revenue (USD Mn) Assessment and Forecast by End User, 2018-2026 1.14.1.6.1.1. Hospitals 1.14.1.6.1.2. Cancer Research Centres 1.14.1.6.1.2.1. Diagnostic Laboratories 1.15. Company Profiles 1.15.1.1. Competition Landscape 1.15.1.2. Global Company Share (USD Mn) Overview, 2018 1.15.1.3. Company Profiles 1.15.1.3.1.1. Biocept, Inc. 1.15.1.3.1.1.1.1. Corporate Overview 1.15.1.3.1.1.1.2. Financial Performance 1.15.1.3.1.1.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.1.1.4. Company Strategy & Channel Management 1.15.1.3.1.2. Qiagen Corporation 1.15.1.3.1.2.1.1. Corporate Overview 1.15.1.3.1.2.1.2. Financial Performance 1.15.1.3.1.2.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.2.1.4. Company Strategy & Channel Management 1.15.1.3.1.3. Roche Diagnostics 1.15.1.3.1.3.1.1. Corporate Overview 1.15.1.3.1.3.1.2. Financial Performance 1.15.1.3.1.3.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.3.1.4. Company Strategy & Channel Management 1.15.1.3.1.4. RainDance Technologies 1.16. 1.15.1.3.1.4.1.1. Corporate Overview 1.15.1.3.1.4.1.2. Financial Performance 1.15.1.3.1.4.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.4.1.4. Company Strategy & Channel Management 1.15.1.3.1.5. Trovagene 1.15.1.3.1.5.1.1. Corporate Overview 1.15.1.3.1.5.1.2. Financial Performance 1.15.1.3.1.5.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.5.1.4. Company Strategy & Channel Management 1.15.1.3.1.6. Genomic Health 1.15.1.3.1.6.1.1. Corporate Overview 1.15.1.3.1.6.1.2. Financial Performance 1.15.1.3.1.6.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.6.1.4. Company Strategy & Channel Management 1.15.1.3.1.7. CellMax Life 1.15.1.3.1.7.1.1. Corporate Overview 1.15.1.3.1.7.1.2. Financial Performance 1.15.1.3.1.7.1.3. Peer Comparison & 3C marketing equation 1.15.1.3.1.7.1.4. Company Strategy & Channel Management Research Sources & Primary Verbatim Inquire further details about this report at: [email protected] About FutureWise Research: We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future. Contact Us: Company Name: FutureWise Research Contact Person: Vinay Thaploo Email: [email protected] Phone: +44 141 628 9353 / +1 970 279 4295 City: Leeds Country: United Kingdom Website: www.futurewiseresearch.com
Liquid biopsy market is anticipated to value over US$ 8.4 billion by the end of 2026 and expanding at a CAGR of over 20% during the forecast period, 2019 to 2026.
© Copyright 2024 Paperzz
